Akero Therapeutics, Inc. (AKRO) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है South San Francisco, CA, United States. वर्तमान CEO हैं Andrew Cheng.
AKRO के पास है IPO तिथि 2019-06-20, 69 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $4.5B.
Akero Therapeutics, Inc. is a cardio-metabolic company focused on developing treatments for nonalcoholic steatohepatitis (NASH) and related metabolic disorders. The company's lead product candidate is efruxifermin (EFX), a fibroblast growth factor 21 analog designed to restore metabolic balance by protecting against cellular stress and regulating the metabolism of lipids, carbohydrates, and proteins throughout the body. Akero is advancing efruxifermin through clinical development, including the Phase 2a BALANCED study evaluating its efficacy in biopsy-confirmed NASH patients. Headquartered in South San Francisco, California, the company was founded in 2017 and rebranded from its former name, Pippin Pharmaceuticals, Inc., in May 2018.
